UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2005
PARTICULARS
Three months ended 30.06.2005 Unaudited
Three months ended 30.06.2004 Unaudited
Year ended 31.03.05 Audited
NET SALES/ OPERATIONAL INCOME
7997.44
4400.00
23944.93
Other Income
18.77
24.37
57.50
TOTAL EXPENDITURE:
6522.40
3764.52
19582.77
(a) (Increase)/decrease in stock in trade
(89.14)
(328.64)
(932.80)
(b) Consumption of Raw Material
5382.29
3074.23
16300.63
(c) Staff Cost
134.96
89.93
441.83
(d) Other expenditure
1094.29
929.00
3773.11
Interest
235.34
202.82
830.54
Depreciation
146.83
89.69
409.85
Profit before tax
1111.64
367.33
3179.27
Provision for Taxation
93.54
28.80
260.27
Net Profit before Deferred Tax
1018.09
338.53
2919.00
Provision for deferred tax
13.67
52.58
271.04
Net Profit
1004.43
285.95
2647.96
Paid up Equity Share Capital
1840.00
Reserves excluding revaluation reserves
8874.14
EPS (Rs.) Basic
5.46
1.83
16.17
Diluted
5.33
1.71
15.64
Notes:
a) During the Quarter under review the turnover
of Company increased by 81.76%, whereas the Net Profit after tax has increased by
251.26% over the Corresponding figures of previous year quarter.
b) During the quarter, the exports turnover
increased by 39.44% over the corresponding quarter of the previous year.
c) Under its ongoing expansion plans, the Company
has successfully put to operation three new manufacturing units, all complying to
USFDA Standards.
d) Company’s new state of art R&D
Center at Mohali (Punjab) is nearing completion and will be put to operations in
the current quarter. Company expects a big boost in its R&D efforts, as it would
augment company’s efforts to tap regulated markets and step up DMF filings.
e) Summary of Investor complaints. Opening:
Nil, Received during the quarter: 7, Resolved: 7, Closing: Nil.
f) The previous year figures have been regrouped
and rearranged wherever necessary.
g) The Company is exclusively in the Pharmaceutical
business segment.
h) The above financial results were taken on
record by the Board at its meeting held on 14th July 2005.
For Ind-Swift Laboratories Limited
Sd/-
Sd/-
Place:Chandigarh
(N.R.MUNJAL)
(V.K.MEHTA)
Date: 14th July, 2005
Managing Director
Jt.Managing Director
To know about our Formulation Division, please visit us at Ind-Swift Limited, our other
group company.
